Sanofi Accused in Class Action of Hiding Zantac’s Cancer Risk

Pharmaceutical companies Sanofi and Boehringer Ingelheim were hit with a proposed class action in a California federal court alleging the drug giants hid cancer risks of popular heartburn medication Zantac.

The complaint came the same day as global health regulators said they were looking into the levels of a probable carcinogen found in ranitidine, which is the generic name for the drug.

Named plaintiffs Christina Garza, Pankaj Khetarpal, Corina Lingerfelt, and Justin Rowe, who each took over-the-counter Zantac products, said the medicine’s “unprecedented sales” were the result of “a deception perpetuated by the drug’s manufacturers on consumers.”

Specifically, the plaintiffs ...